An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Clinical trial NCT05363319 · RECRUITING
Trial details
- NCT number
- NCT05363319
- Sponsor
- Regeneron Pharmaceuticals
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2022-10-26
- Primary completion
- 2028-10-30
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.